Author

Lorant Gonczi 1

1 Semmelweis University,Budapest,Hungary

Benefits of implementing a rapid access clinic in a high volume inflammatory bowel disease center: access, resource utilization and outcomes

Sofia Nene, Lorant Gonczi, Christine Verdon, Jason Reinglas, Rita Kohen, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest Seidman, Alain Bitton, Peter L Lakatos

CHANGES IN THERAPEUTIC STRATEGY AND OUTCOMES IN NEWLY DIAGNOSED PATIENT WITH CROHN’S DISEASE IN THE BIOLOGICAL ERA IN HUNGARY: A NATIONWIDE STUDY BASED ON THE NATIONAL HEALTH INSURANCE FUND DATABASE

Zsuzsanna Kürti, Lorant Gonczi, Zsuzsanna Vegh, Petra Anna Golovics, Petra Fadgyas-Freyler, Judit Gimesi-Országh, Gyula Korponai, Barbara Dorottya Lovasz, Krisztina Barbara Gecse, Peter L Lakatos

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Lorant Gonczi

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Lorant Gonczi, Kata Szántó, Klaudia Farkas, Tamás Molnár, Tamás Szamosi, Eszter Schäfer, Petra Anna Golovics, Barbara Dorottya Lovasz, Mark Juhasz, Árpád V. Patai, Aron Vincze, Patrícia Sarlós, Karoly Palatka, Alexandra Farkas, Gábor Tamás Tóth, Peter L Lakatos, Pal Miheller, Ákos Iliás

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi, László Lakatos, Petra Anna Golovics, Tunde Pandur, Gyula Dávid, Zsuzsanna Erdelyi, Istvan Szita, Peter L Lakatos

FINAL RESULTS ON EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB AFTER ONE-YEAR: RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Krisztina Barbara Gecse, Zsuzsanna Vegh, Zsuzsanna Kürti, Mariann Rutka, Klaudia Farkas, Petra Anna Golovics, Barbara Dorottya Lovasz, Lorant Gonczi, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Mária Papp, Árpád V. Patai, Ágnes Szabone Salamon, Tamá

FINAL RESULTS ON IMMUNOGENICITY PROFILE AND PREDICTORS OF ADA DEVELOPMENT OF BIOSIMILAR INFLIXIMAB DURING THE FIRST 12 MONTHS OF THE THERAPY: RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Petra Anna Golovics, Barbara Dorottya Lovasz, Zsuzsanna Kürti, Mariann Rutka, Zsuzsanna Vegh, Krisztina Barbara Gecse, Klaudia Farkas, János Banai, László Bene, Lorant Gonczi, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Mária Papp, Ágnes Szabone Salamon, Tamás Szamosi, Zo

INCIDENCE, PREDICTIVE FACTORS AND OUTCOMES OF NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A PROSPECTIVE MULTICENTER POPULATION-BASED STUDY FROM HUNGARY

László Lakatos, Lorant Gonczi, Ferenc Izbéki, Árpád V. Patai, Istvan Racz, Beáta Gasztonyi, Lajos Varga-Szabó, Fiona Rozsa, Barbara Dorottya Lovasz, Ákos Iliás, Peter L Lakatos

INCIDENCE, PREDICTIVE FACTORS AND OUTCOMES OF NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A PROSPECTIVE MULTICENTER POPULATION-BASED STUDY FROM HUNGARY

Lorant Gonczi

Item 1 - 10 / 23
1
2 3